	ATTY. DOCKET NO. SHIM008	SERIAL NO. 09/763,286
	APPLICANT Miyata	
	FILING DATE February 20, 2001	GROUP 1623 Unassigned

U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Combet et al. (2000) "Vascular Proliferation and Enhanced Expression of Endothelial Nitric Oxide Synthase in Human Peritoneum Exposed to Long-Term Peritoneal Dialysis." <i>J. Am. Soc. Nephrol.</i> , Vol. 11:717-728.
AB	Combet et al. (1999) "Regulation of Aquaporin-1 and Nitric Oxide Synthase Isoforms in a Rat Model of Acute Peritonitis." <i>J. Am. Soc. Nephrol.</i> , Vol. 10:2185-2196.
AC	Faller (1996) "Amino acid-based peritoneal dialysis solutions." <i>Kidney International</i> , Vol. 50(56):S-81-S-85.
AD	Miyata et al. (2000) "Mechanism of the Inhibitory Effect of OPB-9195 [(±)-2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on Advanced Glycation End Product and Advanced Lipoxidation End Product Formation." <i>J. Am. Soc. Nephrol.</i> , Vol. 11:1719-1725.
AE	Miyata et al. (1996) "Accumulation of Albumin-Linked and Free-Form Pentosidine in the Circulation of Uremic Patients with End-Stage Renal Failure: Renal Implications in the Pathophysiology of Pentosidine." <i>Journal of the American Society of Nephrology</i> , Vol. 7(8):1198-1206.
AF	Miyata et al. (1998) "Accumulation of Carbonyls Accelerates the Formation of Pentosidine, an Advanced Glycation End Product: Carbonyl Stress in Uremia." <i>J. Am. Soc. Nephrol.</i> , Vol. 9:2349-2356.
AG	Miyata et al. (1998) "Autooxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia?" <i>Kidney International</i> , Vol. 54:1290-1295.
AH	Miyata et al. (1999) "Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications." <i>Kidney International</i> , Vol. 55:389-399
AI	Miyata et al. (1997) "Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure." <i>Kidney International</i> , Vol. 51:1170-1181
AJ	Nakayama et al. (1997) "Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD." <i>Kidney International</i> , Vol. 51:182-186.
AK	Wilkie et al. (1997) "Polyglucose Solutions in CAPD." <i>Peritoneal Dialysis International</i> , Vol. 17(2):S47-S50
AL	Yamada et al. (1994) "Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure." <i>Clinical Nephrology</i> , Vol. 42(6):354-361.

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER 	DATE CONSIDERED 12-23-03
EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. SHIM008	SERIAL NO. 09/763,286
	APPLICANT Toshio Miyata	
	INT'L. FILING DATE August 23, 1999	GROUP 1623 To Be Assigned

U.S. PATENT DOCUMENTS


*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PL	AA	5,855,882	01/05/99	Li et al.			
PL	AB	5,861,238	01/19/99	Li et al.			
PL	AC	5,962,245	10/05/99	Li et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
PL	AD	WO 96/31537	10/10/96	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

F:\DOCUMENT\SHIM (Shimizu, formerly SHI)\008\SUPP IDS - 1449 form.doc

EXAMINER 	DATE CONSIDERED 12-23-03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
SHIM008

SERIAL NO. 09/763,286

APPLICANT

Toshio Miyata

FILING DATE

August 28, 2001

GROUP 1623

~~Unassigned~~

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
JJ	AA	5,891,341	04/06/99	Li et al.	210	646	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
JJ	AB	5-105633	04/27/93	Japan	A61K	31/70	Yes No


OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JJ	AC	Niwa et al., "Modification of Beta2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum," <i>Kidney International</i> 49:861-867 (1996)					

RECEIVED
JUL 08 2002
TECH CENTER 1600/2900

F:\DOCUMENT\SHIM (Shimizu, formerly SHI)\008\IDS - PTO-1449.doc

COPY OF PAPERS
ORIGINALLY FILED

EXAMINER 	DATE CONSIDERED 12-22-03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Please type a plus sign (+) inside this box.



JAN 13 2003

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	09/763,286
			Filing Date	August 28, 2001
			First Named Inventor	MIYATA, TOSHIO
			Group Art Unit	1623
			Examiner Name	To Be Assigned
Sheet 1 of 1	Attorney Docket Number	SHIM-008		

RECEIVED
 JAN 14 2003
 PCH CENTER 1600/2600

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
PL	AA	5,827,820		duMoulin	10-27-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
PL	AB		WO 00/69466		Miyata	11-23-2000		Y
PL	AC		JP-4-187158 A		Masuda et al.	07-03-1992		Y
PL	AD		JP 8-131542 A		Izumi et al.	05-28-1996		Y
PL	AE		JP 6-507822 A		duMoulin	09-08-1994		
	AF		JP 63-19149 A		Suzuki et al.	01-26-1988	no translation	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL	AG	LO et al., <i>J. Biol. Chem.</i> 269(51)32299-32306 (1994)	
PL	AH	NIQUETTE et al., <i>J. Am. Water Works Assoc.</i> 90(1):96-97 (1998)	
PL	AI	TANAKA et al., <i>Current Therapeutic Research</i> 58(10)693-7 (1997)	

Examiner Signature	<i>[Signature]</i>	Date Considered	12-23-03
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.